stockportfolio.pro
BMY vs GILD: Which Stock Is the Better Buy?
Bristol-Myers Squibb Company and Gilead Sciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BMY vs GILD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Bristol-Myers Squibb Company (BMY) | Gilead Sciences, Inc. (GILD) | |
|---|---|---|
| Market cap | $124.0B | $166.7B |
| Revenue (latest FY) | $48.19B | $29.44B |
| Net income (latest FY) | $7.05B | $8.51B |
| Revenue growth (5y CAGR) | 2.5% | 3.6% |
| Net margin | 14.6% | 28.9% |
| Return on equity | 38.2% | 37.5% |
| P/E ratio | 17.0 | 18.3 |
| Dividend yield | 4.2% | 2.4% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
See the full BMY vs GILD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BMY's full financials → Open GILD's full financials →More comparisons
Frequently asked questions
Which is bigger, BMY or GILD?
Gilead Sciences, Inc. is larger by market capitalization — $166.7B versus $124.0B.
Which grows faster, BMY or GILD?
Over the last five fiscal years, Gilead Sciences, Inc. grew revenue faster — 3.6%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.